Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Proactive's Stephen Gunnion with the news that the company is expanding its LANCER Phase II/III clinical trial to Brazil, Mexico and Canada, having run the trial exclusively in the United States until now.
Elsley telling Proactive that with coronavirus (COVID-19) there's an urgent need to develop new therapeutics to address the immune-mediated inflammation that results from the virus, particularly in high-risk patients with cardiovascular disease.